Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit

Keyphrases

• Gut Microbial Community 100%
• Specific Taxa 100%
• Lung Cancer Patients 100%
• Substantial Clinical Benefit 100%
• Microbial Signatures 100%
• Lung Cancer 66%
• Ruminococcus 33%
• Akkermansia muciniphila 33%
• Alistipes 33%
• Therapeutic Intervention 16%
• Healthy Controls 16%
• Healthy Individuals 16%
• Predictive Value 16%
• Between-subject 16%
• Healthy Volunteers 16%
• Sequence Data 16%
• Clinical Data 16%
• Cancer Cases 16%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 16%
• Checkpoint Inhibitors 16%
• Future Therapeutics 16%
• Stool Samples 16%
• Gut Microbiome 16%
• Lachnospiraceae 16%
• Random Forest Regression 16%
• Low Diversity 16%
• Faecalibacterium Prausnitzii 16%
• Lung Cancer Screening 16%
• Taxa Abundance 16%
• ROC-AUC 16%
• Clostridiales 16%
• 16S Amplicon Sequencing 16%

Immunology and Microbiology

• Taxon 100%
• Ruminococcus 50%
• Akkermansia muciniphila 50%
• Alistipes 50%
• Normal Human 25%
• Immunotherapy 25%
• Amplicon Sequencing 25%
• Gut Microbiome 25%
• Lachnospiraceae 25%
• Faecalibacterium prausnitzii 25%
• Random Forest 25%
• Clostridiales 25%